Table 1.
Clinical characteristics
| High‐grade serous carcinoma | Low‐grade serous carcinoma | Clear cell carcinoma | Endometrioid carcinoma | Mucinous carcinoma | |
|---|---|---|---|---|---|
| Number of cases, n (%) | 4334 (66.4) | 205 (3.1) | 717 (11.0) | 882 (13.5) | 387 (5.9) |
| Age at diagnosis, years, mean ± SD | 59.7 ± 10.7 | 53.8 ± 12.7 | 56.0 ± 11.4 | 54.8 ± 12.0 | 54.5 ± 14.8 |
| Stage, n (%) | |||||
| I/II | 822 (19.5) | 62 (32.3) | 550 (78.2) | 703 (83.5) | 283 (81.9) |
| III/IV | 3402 (80.5) | 130 (67.7) | 154 (21.8) | 139 (16.5) | 67 (19.1) |
| Unknown | 110 | 13 | 13 | 40 | 37 |
| Macroscopic residual disease, n (%) | |||||
| Absent | 1028 (43.7) | 64 (49.6) | 349 (81.0) | 393 (88.3) | 163 (77.2) |
| Present | 1323 (54.3) | 65 (50.4) | 82 (19.0) | 52 (11.7) | 51 (23.8) |
| Unknown | 1983 | 76 | 286 | 437 | 173 |
| Outcome | |||||
| Five year survival, % ± SE1 | 40.7 ± 0.8 | 61.9 ±3.7 | 63.4 ± 1.9 | 81.0 ± 1.5 | 65.3 ± 2.7 |
| Total months followed for censored patients, months, mean ± SD1 | 87 ± 41 | 80 ± 43 | 104 ± 39 | 101 ± 39 | 97 ± 41 |
| p16 expression, n (%) | |||||
| Heterogeneous | 1627 (37.5) | 167 (81.5) | 471 (65.7) | 676 (76.7) | 171 (44.2) |
| Absent | 267 (6.2) | 25 (12.2) | 146 (20.4) | 127 (14.4) | 194 (50.1) |
| Block | 2440 (56.3) | 13 (6.3) | 100 (13.9) | 79 (8.9) | 22 (5.7) |
1
Follow‐up is right‐censored at 12 years post‐diagnosis.